Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve OS among patients with metastatic pancreatic adenocarcinoma. For this randomized phase 1b/2 study (ClinicalTrials.gov Identifier: NCT01959139), researchers evaluated the safety and efficacy of PEGPH20 with mFOLFIRINOX vs mFOLFIRINOX alone among 138 patients with good performance status and adequate organ function. Read more . . .